$3.93 0.0 0.8%
Last Trade - 02/03/21
| Market Cap | £40.5m |
| Enterprise Value | £35.6m |
| Revenue | £226k |
| Position in Universe | 5444th / 6633 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.43 | 0.90 | 0.58 | 0.48 | 0.63 | 0.71 | 0.12 | 0.50 | +10.7% | ||
| +1,132 | ||||||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
BioCardia, Inc. is a clinical-stage regenerative medicine company engaged in developing therapeutics for cardiovascular diseases. The Company's therapeutic portfolio consists of the CardiAMP and CardiALLO cell therapies. The Company's lead therapeutic candidate is the CardiAMP Cell Therapy System (CardiAMP) and focuses on the Phase III trial for CardiAMP in ischemic systolic heart failure. The Company's CardiALLO Cell Therapy System (CardiALLO), is an allogeneic off the shelf mesenchymal stem cell product candidate from other donors. The Company’s products also include Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | January 12, 1994 |
| Public Since | November 13, 1996 |
| No. of Shareholders: | 201 |
| No. of Employees: | 20 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Capital Market |
| Shares in Issue | 14,467,630 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 125 Shoreway Rd Ste B, SAN CARLOS, 94070-2718, United States |
| Web | http://www.biocardia.com/ |
| Phone | +1 650 2260120 |
| Contact | () |
| Auditors | KPMG LLP |
As of 02/03/21, shares in BioCardia Inc are trading at $3.93, giving the company a market capitalisation of £40.5m. This share price information is delayed by 15 minutes.
Shares in BioCardia Inc are currently trading at $3.93 and the price has moved by 6.27% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the BioCardia Inc price has moved by -13.83% over the past year.
There are no analysts currently covering BioCardia Inc.
BioCardia Inc is scheduled to issue upcoming financial results on the following dates:
BioCardia Inc does not currently pay a dividend.
BioCardia Inc does not currently pay a dividend.
BioCardia Inc does not currently pay a dividend.
To buy shares in BioCardia Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in BioCardia Inc are currently trading at $3.93, giving the company a market capitalisation of £40.5m.
Here are the trading details for BioCardia Inc:
Based on an overall assessment of its quality, value and momentum, BioCardia Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in BioCardia Inc are currently priced at $3.93. At that level they are trading at 0.23% discount to the analyst consensus target price of 0.00.
Analysts covering BioCardia Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.617 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioCardia Inc. Over the past six months, the relative strength of its shares against the market has been 51.74%. At the current price of $3.93, shares in BioCardia Inc are trading at 28.48% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for BioCardia Inc.
BioCardia Inc's management team is headed by:
Here are the top five shareholders of BioCardia Inc based on the size of their shareholding:
